Mechanism of effective combination radio-immunotherapy against 9464D-GD2, an immunologically cold murine neuroblastoma.

Autor:	Aiken TJ; Department of General Surgery, University of Wisconsin Hospitals and Clinics, Madison, Wisconsin, USA.; Department of Human Oncology, University of Wisconsin-Madison, Madison, Wisconsin, USA., Erbe AK; Department of Human Oncology, University of Wisconsin-Madison, Madison, Wisconsin, USA., Zebertavage L; Department of Human Oncology, University of Wisconsin-Madison, Madison, Wisconsin, USA., Komjathy D; Department of Human Oncology, University of Wisconsin-Madison, Madison, Wisconsin, USA., Feils AS; Department of Human Oncology, University of Wisconsin-Madison, Madison, Wisconsin, USA., Rodriguez M; Department of Human Oncology, University of Wisconsin-Madison, Madison, Wisconsin, USA., Stuckwisch A; Department of Human Oncology, University of Wisconsin-Madison, Madison, Wisconsin, USA., Gillies SD; Provenance Biopharmaceuticals, Carlisle, Massachusetts, USA., Morris ZS; Department of Human Oncology, University of Wisconsin-Madison, Madison, Wisconsin, USA., Birstler J; Biostatistics and Medical Informatics, University of Wisconsin-Madison, Madison, Wisconsin, USA., Rakhmilevich AL; Department of Human Oncology, University of Wisconsin-Madison, Madison, Wisconsin, USA., Sondel PM; Department of Human Oncology, University of Wisconsin-Madison, Madison, Wisconsin, USA pmsondel@humonc.wisc.edu.; Department of Pediatrics, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Jazyk:	angličtina
Zdroj:	Journal for immunotherapy of cancer [J Immunother Cancer] 2022 May; Vol. 10 (5).
DOI:	10.1136/jitc-2022-004834
Abstrakt:	Background: Most pediatric cancers are considered immunologically cold with relatively few responding to immune checkpoint inhibition. We recently described an effective combination radio-immunotherapy treatment regimen ( c ombination a daptive- i nnate immunotherapy r egimen (CAIR)) targeting adaptive and innate immunity in 9464D-GD2, an immunologically cold model of neuroblastoma. Here, we characterize the mechanism of CAIR and the role of major histocompatibility complex class I (MHC-I) in the treatment response. Methods: Mice bearing GD2-expressing 9464D-GD2 tumors were treated with CAIR (external beam radiotherapy, hu14.18-IL2 immunocytokine, CpG, anti-CD40, and anti-CTLA4) and tumor growth and survival were tracked. Depletion of specific immune cell lineages, as well as testing in immunodeficient R2G2 mice, were used to determine the populations necessary for treatment efficacy. Induction of MHC-I expression in 9464D-GD2 cells in response to interferon-γ (IFN-γ) and CAIR was measured in vitro and in vivo , respectively, by flow cytometry and quantitative real-time PCR. A cell line with IFN-γ-inducible MHC-I expression (9464D-GD2-I) was generated by transfecting a subclone of the parental cell line capable of expressing MHC-I with GD2 synthase and was used in vivo to assess the impact of MHC-I expression on responsiveness to CAIR. Results: CAIR cures some mice bearing small (50 mm 3 ) but not larger (100 mm 3 ) 9464D-GD2 tumors and these cured mice develop weak memory responses against tumor rechallenge. Early suppression of 9464D-GD2 tumors by CAIR does not require T or natural killer (NK) cells, but eventual tumor cures are NK cell dependent. Unlike the parental 9464D cell line, 9464D-GD2 cells have uniformly very low MHC-I expression at baseline and fail to upregulate expression in response to IFN-γ. In contrast, 9464D-GD2-I upregulates MHC-I in response to IFN-γ and is less responsive to CAIR. Conclusion: Treatment with CAIR cures 9464D-GD2 tumors in a NK cell dependent manner and induction of MHC-I by tumors cells was associated with decreased efficacy. These results demonstrate that the early tumor response to this regimen is T and NK cell independent, but that NK cells have a role in generating lasting cures in the absence of MHC-I expression by tumor cells. Further strategies to better inhibit tumor outgrowth in this setting may require further NK activation or the ability to engage alternative immune effector cells. Competing Interests: Competing interests: SDG declares employment and ownership interests in Provenance Biopharmaceuticals. (© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu